Skip to main content

Table 2 Primary and secondary outcomes

From: Residual renal function in chronic dialysis is not associated with reduced erythropoietin-stimulating agent dose requirements: a cross-sectional study

Parameter

Number of patients

Median ERI

IQR

P-value

Primary Outcome

 Residual renal function

  Present

36

9.5

(7.0–15.3)

0.45

  Absent

64

11.0

(6.3–16.2)

Secondary Outcomes

 Dialysis modality

  HD

67

10.8

(8.5–14.3)

0.84

  PD

33

10.2

(5.9–16.0)

 RAS blocker use

52

11.6

(7.9–16.7)

 

  ACE inhibitor

43

11.8

(8.1–16.8)

0.10

  ARB

9

11.0

(6.0–13.7)

  No RAS blocker use

48

9.2

(6.1–15.2)

 PTH category (pmol/L)

   < 17

19

13.5

(6.5–16.8)

0.73

  17–76.5

34

9.6

(6.2–14.9)

   > 76.5

28

9.1

(6.8–15.3)

 Systemic inflammation

  Present

14

16.5

(11.0–18.7)

<0.01

  Absent

86

9.5

(6.0–14.9)

 Underlying kidney disease

  ESKD (cause unknown)

66

10.8

(7.8–15.4)

0.32

  Renal vascular disease

14

8.4

(5.2–14.3)

  Cystic kidney disease

4

6.9

(3.9–13.2)

  Autoimmune disease

4

16.5

(12.0–17.9)

  Other and unknown

12

9.1

(6.4–15.5)

  1. ERI erythropoietin resistance index; IQR interquartile range; HD haemodialysis; PD peritoneal dialysis; ACE angiotensin-converting enzyme; RAS renin angiotensin system; PTH parathyroid hormone; ESKD end-stage kidney disease. ‘Other’ refers to reflux nephropathy, single kidney, renal cortical necrosis, pre-eclampsia, drug overdose and unknown aetiology. Systemic inflammation was defined as serum ferritin >150 ng/mL and serum CRP >10 mg/L and serum albumin <35 g/L